(NASDAQ: BBIO) Bridgebio Pharma's forecast annual revenue growth rate of 54.26% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.55%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.69%.
Bridgebio Pharma's revenue in 2026 is $713,069,000.On average, 25 Wall Street analysts forecast BBIO's revenue for 2026 to be $204,675,385,278, with the lowest BBIO revenue forecast at $184,872,504,162, and the highest BBIO revenue forecast at $229,893,269,424. On average, 23 Wall Street analysts forecast BBIO's revenue for 2027 to be $344,839,904,136, with the lowest BBIO revenue forecast at $284,434,274,670, and the highest BBIO revenue forecast at $476,207,486,664.
In 2028, BBIO is forecast to generate $517,650,831,152 in revenue, with the lowest revenue forecast at $435,350,604,598 and the highest revenue forecast at $741,483,988,882.